MNOV

Business Context and Reporting Period

Company: MEDICINOVA INC (MNOV)
Filing Type: Form 8-K (Current Report)
Date of Report: January 11, 2021
Event: Entry into a Material Definitive Agreement for a private placement of equity securities.

Key Financial Metrics and Transaction Details

• Transaction Value: $20 million in common stock.
• Investor: 3D Opportunity Master Fund.
• Expected Closing Date: January 29, 2021 (subject to customary conditions).
• Pricing Mechanism: The price per share is the lower of:
  • The average closing price over the five business days prior to Board approval (Determination Date).
  • The average closing price over the five business days prior to the closing date.
  Price Floor: If the closing average is lower than the determination average and 90% of the closing price the day prior to the Determination Date, the price shall be the Base Price (90% of the prior day's close).
• Registration: Shares issued under Section 4(a)(2) and Rule 506 exemptions; Company required to file a registration statement for resale.

Material Changes and Agreements

The filing details the execution of two primary agreements on January 11, 2021:

1. Securities Purchase Agreement: Establishes the terms for the $20 million private placement.
2. Shareholder Rights Agreement:
   • Board Observer: Investor may appoint a board observer starting one year after the signing date, provided they maintain beneficial ownership of at least 5% of outstanding shares. The observer term is the shorter of two years or until ownership falls below the threshold.
   • Financing Rights: For one year post-signing, the Company cannot entertain financing proposals unless they significantly enhance stockholder value. If such a proposal is pursued, the Investor has a right of first offer and a right of first look regarding third-party financing.

Guidance, Outlook, and Risks

Management Commentary: The filing includes a press release (Exhibit 99.1) announcing the transaction but does not contain specific forward-looking financial guidance or operational outlook beyond the transaction details.

Risks and Contingencies:

• The transaction is subject to customary closing conditions.
• Representations and warranties in the agreements are for risk allocation between parties and should not be relied upon as factual statements of the Company's condition.
• Information regarding representations may change after the agreement date.

Investor Verification Checklist

• Verify the final share price and total number of shares issued upon the expected closing on January 29, 2021.
• Confirm the filing of the registration statement for resale of the shares as required by the Purchase Agreement.
• Monitor the Investor's ownership percentage to determine if the 5% threshold for the Board Observer right is met one year post-signing.
• Review the full text of the Press Release (Exhibit 99.1) for additional context on the use of proceeds.